ArticleJournal of magnetic resonance imaging : JMRI2026
Magnetic Resonance Elastography in Breast Cancer: A Prospective Study on Optimal Imaging Frequency Selection and Differentiation of Molecular Subtypes.
Article in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial for "Magnetic Resonance Elastography in Breast Cancer: A Prospective Study on Optimal Imaging Frequency Selection and Differentiation of Molecular Subtypes".Journal of magnetic resonance imaging : JMRI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMR elastography (MRE) has applications in breast cancer, but its optimal frequency and value in discriminating molecular subtypes remain unclear. PURPOSE: To identify the preferable breast MRE frequency and evaluate MRE parameters in the precision diagnosis of breast cancer. STUDY TYPE: Prospective. POPULATION: One hundred fifty-four female patients (mean age 50 ± 10.67 years) were enrolled, including five with bilateral cancer, yielding 159 lesions. FIELD STRENGTH/SEQUENCE: 3.0 T, fast gradient-echo for DCE-MRI, single-shot EPI for DWI/ADC, SE-EPI for multifrequency MRE. ASSESSMENT: The image quality of 10 frequency MRE sets was assessed (including overall image quality, diagnostic confidence, artifact impact, and signal-to-noise ratio). Stiffness (c) and viscosity (φ) were measured at the optimal frequency and compared across clinicopathological subgroups. STATISTICAL TESTS: Independent-sample t-tests or one-way analysis of variance, Mann-Whitney U or Kruskal-Wallis H tests, Friedman test, χ
resultsThe 40-70 Hz multifrequency band demonstrated significantly superior image quality compared with all other bands. Subgroup analyses showed that c and φ differed significantly between ER-positive and ER-negative groups (c values: 2.54 (2.17-2.86) vs. 2.80 (2.37-3.30) m/s; φ values: 1.17 ± 0.21 vs. 1.24 ± 0.22 radians) and across groups with different Ki-67 expression levels (c values: 2.54 ± 0.54 vs. 2.77 ± 0.57 m/s), T stage, molecular subtypes (c values: 2.55 (2.20-2.82) vs. 2.69 (2.20-2.96) vs. 2.94 (2.52-3.33) m/s), and enhancement patterns (c values: 2.34 ± 0.41 vs. 2.73 ± 0.58 m/s). Multivariable analysis identified c [OR: 5.37 (2.13-15.54)] and age group [OR: 0.27 (0.09-0.82)] as significant independent predictors of triple-negative breast cancer, and a predictive model incorporating these variables demonstrated an AUC of 0.739 in the training set and 0.700 in the validation set. DATA
conclusionThe 40-70 Hz multifrequency protocol may offer favorable image quality for breast MRE. MRE parameters, particularly stiffness, show potential for characterizing tissue biomechanical properties and could assist in distinguishing molecular subtypes. EVIDENCE LEVEL: 1. STAGE OF TECHNICAL EFFICACY: Stage 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.